Cheetah Medical Announces Successful Completion of Key Sepsis Clinical Trial

March 14, 2019 Off By BusinessWire

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a Massachusetts-based leader in non-invasive fluid
management, today announced it has concluded enrollment for the Fluid
Responsiveness Evaluation in Sepsis-associated Hypotension (FRESH) trial
following successful primary outcomes.

The FRESH study, led by Ivor Douglas, M.D., FRCP, Denver
Health Medical Center, has enrolled approximately 120 patients over
the past two years and is the first multi-center, prospective,
randomized, controlled study to evaluate using fluid responsiveness to
drive fluid therapy in critically ill septic patients with refractory
hypotension in an ICU setting.

“We are very confident in these results and look forward to the final
analysis,” said Dr. Douglas. “As this is the first study of its kind, we
expect its findings to have a significant impact on the fluid management
of patients.”

“Every day, clinicians must decide whether to give fluids or
vasopressors to treat hypotensive patients,” said Douglas M. Hansell,
M.D., M.P.H., Chief Physician Executive at Cheetah Medical. “The FRESH
study was designed to determine whether using stroke-volume guided
dynamic measures of fluid effectiveness can help clinicians improve
outcomes in these difficult patients.”

The full results of the FRESH study will be submitted for publication in
a medical journal anticipated for late 2019.

About the FRESH Study

The Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
study (FRESH) is a prospective, randomized, controlled study evaluating
the incidence of fluid responsiveness (FR) in critically ill patients
with sepsis or septic shock. Upon completion, the FRESH study will
assess the mean difference in fluid balance at intensive care unit (ICU)
discharge and associated patient outcomes, based on a dynamic assessment
of FR in septic patients with refractory hypotension in an ICU setting.

About Cheetah Medical

Cheetah Medical is the pioneer and leading global provider of 100
percent non-invasive fluid management monitoring technologies, designed
for use in critical care, operating room and emergency department
settings. The CHEETAH Starling™ SV is fast becoming the gold standard in
fluid management, as it provides immediate, dynamic assessments of fluid
responsiveness, enabling clinicians to make more confident and informed
treatment for their patients. Moreover, recent research from the
University of Kansas Medical Center has shown effective fluid management
can reduce hospital ICU stays by an average of 2.89 days, reduce risk of
mechanical ventilation and initiation of acute dialysis, saving over
$14,000 in medical costs per patient. The company’s fluid
management systems currently make an impact in more than 400 hospitals
throughout the U.S. and in 30 countries worldwide.